Loading...
OTCMSNWV
Market cap232mUSD
Jan 22, Last price  
27.30USD
1D
1.04%
Jan 2017
15,508.92%
IPO
420.00%
Name

SANUWAVE Health

Chart & Performance

D1W1MN
OTCM:SNWV chart
P/E
—
P/S
11.42
EPS
—
Div Yield, %
—
Shrs. gr., 5y
39.64%
Rev. gr., 5y
61.61%
Revenues
20m
+21.84%
000660,725728,446802,572769,217800,029847,367965,5011,376,063738,5271,850,0601,028,7304,057,47113,010,00016,742,00020,398,000
Net income
-26m
L+150.72%
21,987-35,692-26,550-6,153,040-14,922,441-10,238,797-6,401,494-11,299,721-5,974,080-4,810,285-6,439,040-5,537,936-11,631,394-12,266,020-34,078,064-27,259,000-10,293,000-25,807,000
CFO
-5m
L-73.57%
-4,072-22,072-41,923-6,271,932-5,867,276-8,831,699-4,290,121-3,924,204-6,678,369-3,473,456-3,199,453-1,528,971-3,621,172-6,410,758-12,718,292-6,409,000-17,169,000-4,538,000
Earnings
Mar 20, 2025

Profile

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
URL
https://sanuwave.com/
IPO date
Nov 07, 2008
Employees
38
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
20,398
21.84%
16,742
28.69%
Cost of revenue
20,186
24,928
Unusual Expense (Income)
NOPBT
212
(8,186)
NOPBT Margin
1.04%
Operating Taxes
4
2
Tax Rate
1.89%
NOPAT
208
(8,188)
Net income
(25,807)
150.72%
(10,293)
-62.24%
Dividends
Dividend yield
Proceeds from repurchase of equity
100
BB yield
-0.80%
Debt
Debt current
31,452
40,668
Long-term debt
984
876
Deferred revenue
347
230
Other long-term liabilities
Net debt
30,639
40,391
Cash flow
Cash from operating activities
(4,538)
(17,169)
CAPEX
1,022
Cash from investing activities
21
332
Cash from financing activities
5,211
17,384
FCF
10,640
(21,681)
Balance
Cash
1,797
1,153
Long term investments
Excess cash
777
316
Stockholders' equity
(219,020)
(193,760)
Invested Capital
208,133
194,086
ROIC
0.10%
ROCE
EV
Common stock shares outstanding
793,851
549,471
Price
0.01
-42.98%
0.02
-86.59%
Market cap
10,320
-17.62%
12,528
-85.78%
EV
40,959
52,919
EBITDA
1,240
(7,234)
EV/EBITDA
33.03
Interest
15,623
14,132
Interest/NOPBT
7,369.34%